Aprea Therapeutics, Inc. (APRE)
NASDAQ: APRE · Real-Time Price · USD
2.090
0.00 (0.01%)
Mar 31, 2025, 10:46 AM EDT - Market open
Aprea Therapeutics Stock Forecast
APRE's stock price has decreased by -65.57% in the past year and price targets may not have had time to catch up.
Stock Price Forecast
The 2 analysts with 12-month price forecasts for Aprea Therapeutics stock have an average target of 15.5, with a low estimate of 11 and a high estimate of 20. The average target predicts an increase of 641.56% from the current stock price of 2.09.
Analyst Consensus: Strong Buy
* Price targets were last updated on Jan 15, 2025.
Analyst Ratings
The average analyst rating for Aprea Therapeutics stock from 2 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Oct '24 | Nov '24 | Dec '24 | Jan '25 | Feb '25 | Mar '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 1 | 1 | 1 | 1 | 1 | 1 |
| Buy | 1 | 1 | 1 | 1 | 1 | 1 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 2 | 2 | 2 | 2 | 2 | 2 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $20 | Strong Buy | Reiterates | $20 | +856.85% | Jan 15, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $20 | Strong Buy | Reiterates | $20 | +856.85% | Dec 17, 2024 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $20 | Strong Buy | Reiterates | $20 | +856.85% | Nov 18, 2024 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $20 | Strong Buy | Reiterates | $20 | +856.85% | Oct 24, 2024 |
| Wedbush | Wedbush | Buy Reiterates $11 | Buy | Reiterates | $11 | +426.27% | Aug 13, 2024 |
Financial Forecast
Revenue This Year
1.37M
from 583.23K
Increased by 134.21%
Revenue Next Year
918.00K
from 1.37M
Decreased by -32.80%
EPS This Year
-2.60
from -3.95
EPS Next Year
-1.52
from -2.60
Revenue Forecast
| Revenue | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|---|
| High | 1.9M | 1.9M | 1.9M | |||
| Avg | 1.4M | 918,000 | 918,000 | |||
| Low | 900,620 | n/a | n/a |
Revenue Growth
| Revenue Growth | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|---|
| High | 224.1% | 38.4% | 105.9% | |||
| Avg | 134.2% | -32.8% | - | |||
| Low | 54.4% | - | - |
EPS Forecast
| EPS | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | -2.51 | -1.00 | -0.90 | ||
| Avg | -2.60 | -1.52 | -1.77 | ||
| Low | -2.65 | -2.50 | -2.56 |
EPS Growth
| EPS Growth | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | - | - | - | ||
| Avg | - | - | - | ||
| Low | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.